| Catalog Number | KC-4225 |
|---|---|
| Cell Line Name | Jurkat-NFAT-Luc2-CD3D-CD3E-KO-2A3-Cell-Line |
| Host Cell Line | Jurkat-NFAT-Luc2-CD3D-KO-1B1 |
| Description | Stable Jurkat-NFAT-Luc2-CD3D-KO clone with human CD3E gene knockout, No.2A3 |
| Quantity | One vial of frozen cells (≥2-106/vial) |
| Stability | Stable in culture over a minimum of 10 passages |
| Application | Drug screening and biological assays |
| Freezing Medium | RPMI1640+20% FBS+10% DMSO |
| Propagation Medium | RPMI1640+10% FBS+300μg/mL Hygromycin |
| Selection Marker | N/A |
| Morphology | Lymphoblast |
| Subculture | Split saturated culture 1:4-1:6 every 2-3 days; seed out at about 1-3 × 105 cells/mL |
| Incubation | 37 °C with 5% CO2 |
| Storage | Liquid nitrogen immediately upon receiving |
| Doubling Time | Approximately 26 hours |
| Mycoplasma Status | Negative |
| In Vivo Validation | NA |
Figure 1: Characterization of CD3D knockout in Jurkat-NFAT-Luc2 using PCR sequencing.
Figure 2: Characterization of CD3D knockout in Jurkat-NFAT-Luc2 using RT-PCR sequencing.
Figure 3: Characterization of CD3D knockout in Jurkat-NFAT-Luc2 using FACS.
Figure 4: Characterization of CD3E knockout in Jurkat-NFAT-Luc2-CD3D-KO using PCR sequencing.
Figure 5: Characterization of CD3E knockout in Jurkat-NFAT-Luc2-CD3D-KO using RT-PCR sequencing.
Figure 6: Chareacterization of Jurkat-NFAT-Luc2-CD3-KO clone and Jurkat-NFAT-Luc2 parental cells treated by 20μg/mL OKT3 for 6 hours using Bright-Glo system.
Figure 7. Chareacterization of Jurkat-NFAT-Luc2-CD3-KO clones and Jurkat-NFAT-Luc2 cell line were seeded into the 96-well plate, and treated with OKT3 at a maximum concentration of 20μg/mL for 16 hours, then readout with Bright-Glo system.
